AbbVie Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ABBV New York 2834 https://www.abbvie.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for AbbVie Inc

AbbVie to Present at the Goldman Sachs 44th Annual Global Healthcare Conference - Jun 6th, 2023 12:00 pm
$300 a Month in These 3 Stocks Could Make You a Millionaire by Retirement - Jun 6th, 2023 11:30 am
Even Mark Cuban Can’t Fix This Broken Drug System - Jun 5th, 2023 1:46 pm
AbbVie (NYSE:ABBV) shareholders have earned a 18% CAGR over the last three years - Jun 4th, 2023 1:00 pm
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree - Jun 2nd, 2023 5:17 pm
S&P 500 Dividend Aristocrats List: Sorted By Hedge Fund Popularity - Jun 2nd, 2023 3:55 pm
14 Best Annual Dividend Stocks To Buy Now - Jun 2nd, 2023 3:49 pm
Why AbbVie and Amgen Are Moving Lower Today - Jun 1st, 2023 4:50 pm
AstraZeneca (AZN) Discontinues Brazikumab Development - Jun 1st, 2023 2:40 pm
UPDATE 2-Coherus BioSciences to launch Humira biosimilar at 85% discount - Jun 1st, 2023 1:37 pm
UPDATE 1-AstraZeneca to stop developing Crohn's disease drug - Jun 1st, 2023 6:36 am
Phase 2 Study of Upadacitinib (RINVOQ®) Alone or as a Combination Therapy Meets Primary and Key Secondary Endpoints in Patients with Systemic Lupus Erythematosus - May 31st, 2023 6:30 am
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know - May 29th, 2023 1:00 pm
10 Best June Dividend Stocks To Buy - May 29th, 2023 10:52 am
Louis Navellier’s 2023 Portfolio: 15 Growth Stocks to Watch - May 26th, 2023 7:56 pm
Is AbbVie Inc.'s (NYSE:ABBV) ROE Of 57% Impressive? - May 26th, 2023 1:01 pm
2 Dividend Kings on Sale That Are Yielding More Than 4% - May 25th, 2023 1:37 pm
2 Top Dividend Kings to Buy for the Long Haul - May 25th, 2023 1:00 pm
New England Journal of Medicine Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib (RINVOQ®) in Crohn's Disease - May 25th, 2023 12:45 pm
The Zacks Analyst Blog Highlights AbbVie, Intel, Qualcomm, Regeneron and CME Group - May 25th, 2023 10:38 am